Detection of the c-myc oncogene product in testicular cancer
Author Information
Author(s): K. Sikora, G. Evan, J. Stewart, J.V. Watson
Primary Institution: Ludwig Institute for Cancer Research and MRC Clinical Oncology and Radiotherapeutics Unit
Hypothesis
The study investigates the expression of the c-myc oncogene product in testicular cancer tissues.
Conclusion
The c-myc oncogene product is expressed differently in various types of testicular tumors, with significant implications for understanding tumor differentiation.
Supporting Evidence
- Monoclonal antibodies were constructed to study the c-myc oncogene product in testicular cancer.
- Normal testes showed low levels of the c-myc protein, while seminomas exhibited increased staining.
- Malignant teratomas displayed variable expression of the c-myc protein, with some areas showing intense staining.
Takeaway
This study looked at how a specific cancer protein behaves in testicular cancer, finding that it acts differently in different types of tumors.
Methodology
Monoclonal antibodies were developed to detect the c-myc protein in archival testicular tumor samples using immunohistology.
Limitations
The study is limited by the retrospective nature of the archival samples and the variability in staining intensity among different tumors.
Participant Demographics
Patients with testicular cancer, specifically those attending the Testicular Tumour Clinic.
Want to read the original?
Access the complete publication on the publisher's website